| Dr Randee E Lipman, MD | |
|
2101 N Waldron St, Hutchinson, KS 67502-1197 | |
| (620) 669-2500 | |
| (620) 694-4225 |
| Full Name | Dr Randee E Lipman |
|---|---|
| Gender | Female |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 41 Years |
| Location | 2101 N Waldron St, Hutchinson, Kansas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1598701922 | NPI | - | NPPES |
| 100125840G | Medicaid | KS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 04-23573 (Kansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hutchinson Regional Medical Center Inc | Hutchinson, KS | Hospital |
| Via Christi Hospital-wichita | Wichita, KS | Hospital |
| Newton Medical Center | Newton, KS | Hospital |
| Wesley Medical Center | Wichita, KS | Hospital |
| St Luke Hospital & Living Center | Marion, KS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hutchinson Physicians Pa | 4183941818 | 20 |
| Hutchinson Clinic P A Inc | 5597658492 | 108 |
| Cardiovascular Care Pa | 7315963899 | 15 |
News Archive
A drug designed to target cancerous plasma cells appears promising in treating multiple myeloma, a type of blood cancer. A multi-center study looked at the drug elotuzumab, an antibody which is designed to target CS1, a protein on the surface of malignant plasma cells. The antibody has the potential to attach to malignant plasma cells and eliminates them by an immune mechanism.
Fluxion Biosciences announced today a product expansion for its IonFlux automated patch clamp system which includes full automation and walk-away capability.
The U.S. Food and Drug Administration today approved the first genetic test that can help some colorectal cancer (CRC) patients and their doctors determine if the drug Erbitux (cetuximab) would be an effective treatment based on the absence of a gene mutation. The therascreen KRAS RGQ PCR Kit can provide information about the KRAS gene mutation in patients whose CRC has spread to other parts of their body (metastasized).
New research draws attention to the continuing and urgent health emergency facing Palestinians living under occupation, especially the health and wellbeing issues surrounding refugees from the occupied Palestinian territories. Abstracts of the research, which were presented at the fourth meeting of The Lancet Palestinian Health Alliance in March 2012, are published online in The Lancet.
› Verified 1 days ago
| Entity Name | Hutchinson Regional Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972605285 PECOS PAC ID: 0648181198 Enrollment ID: O20040119000578 |
News Archive
A drug designed to target cancerous plasma cells appears promising in treating multiple myeloma, a type of blood cancer. A multi-center study looked at the drug elotuzumab, an antibody which is designed to target CS1, a protein on the surface of malignant plasma cells. The antibody has the potential to attach to malignant plasma cells and eliminates them by an immune mechanism.
Fluxion Biosciences announced today a product expansion for its IonFlux automated patch clamp system which includes full automation and walk-away capability.
The U.S. Food and Drug Administration today approved the first genetic test that can help some colorectal cancer (CRC) patients and their doctors determine if the drug Erbitux (cetuximab) would be an effective treatment based on the absence of a gene mutation. The therascreen KRAS RGQ PCR Kit can provide information about the KRAS gene mutation in patients whose CRC has spread to other parts of their body (metastasized).
New research draws attention to the continuing and urgent health emergency facing Palestinians living under occupation, especially the health and wellbeing issues surrounding refugees from the occupied Palestinian territories. Abstracts of the research, which were presented at the fourth meeting of The Lancet Palestinian Health Alliance in March 2012, are published online in The Lancet.
› Verified 1 days ago
| Entity Name | Hutchinson Clinic P A Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043298474 PECOS PAC ID: 5597658492 Enrollment ID: O20040204000969 |
News Archive
A drug designed to target cancerous plasma cells appears promising in treating multiple myeloma, a type of blood cancer. A multi-center study looked at the drug elotuzumab, an antibody which is designed to target CS1, a protein on the surface of malignant plasma cells. The antibody has the potential to attach to malignant plasma cells and eliminates them by an immune mechanism.
Fluxion Biosciences announced today a product expansion for its IonFlux automated patch clamp system which includes full automation and walk-away capability.
The U.S. Food and Drug Administration today approved the first genetic test that can help some colorectal cancer (CRC) patients and their doctors determine if the drug Erbitux (cetuximab) would be an effective treatment based on the absence of a gene mutation. The therascreen KRAS RGQ PCR Kit can provide information about the KRAS gene mutation in patients whose CRC has spread to other parts of their body (metastasized).
New research draws attention to the continuing and urgent health emergency facing Palestinians living under occupation, especially the health and wellbeing issues surrounding refugees from the occupied Palestinian territories. Abstracts of the research, which were presented at the fourth meeting of The Lancet Palestinian Health Alliance in March 2012, are published online in The Lancet.
› Verified 1 days ago
| Entity Name | Cardiovascular Care Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902877038 PECOS PAC ID: 7315963899 Enrollment ID: O20051024000724 |
News Archive
A drug designed to target cancerous plasma cells appears promising in treating multiple myeloma, a type of blood cancer. A multi-center study looked at the drug elotuzumab, an antibody which is designed to target CS1, a protein on the surface of malignant plasma cells. The antibody has the potential to attach to malignant plasma cells and eliminates them by an immune mechanism.
Fluxion Biosciences announced today a product expansion for its IonFlux automated patch clamp system which includes full automation and walk-away capability.
The U.S. Food and Drug Administration today approved the first genetic test that can help some colorectal cancer (CRC) patients and their doctors determine if the drug Erbitux (cetuximab) would be an effective treatment based on the absence of a gene mutation. The therascreen KRAS RGQ PCR Kit can provide information about the KRAS gene mutation in patients whose CRC has spread to other parts of their body (metastasized).
New research draws attention to the continuing and urgent health emergency facing Palestinians living under occupation, especially the health and wellbeing issues surrounding refugees from the occupied Palestinian territories. Abstracts of the research, which were presented at the fourth meeting of The Lancet Palestinian Health Alliance in March 2012, are published online in The Lancet.
› Verified 1 days ago
| Entity Name | Kansas Medical Center Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255380127 PECOS PAC ID: 2668476862 Enrollment ID: O20061109000659 |
News Archive
A drug designed to target cancerous plasma cells appears promising in treating multiple myeloma, a type of blood cancer. A multi-center study looked at the drug elotuzumab, an antibody which is designed to target CS1, a protein on the surface of malignant plasma cells. The antibody has the potential to attach to malignant plasma cells and eliminates them by an immune mechanism.
Fluxion Biosciences announced today a product expansion for its IonFlux automated patch clamp system which includes full automation and walk-away capability.
The U.S. Food and Drug Administration today approved the first genetic test that can help some colorectal cancer (CRC) patients and their doctors determine if the drug Erbitux (cetuximab) would be an effective treatment based on the absence of a gene mutation. The therascreen KRAS RGQ PCR Kit can provide information about the KRAS gene mutation in patients whose CRC has spread to other parts of their body (metastasized).
New research draws attention to the continuing and urgent health emergency facing Palestinians living under occupation, especially the health and wellbeing issues surrounding refugees from the occupied Palestinian territories. Abstracts of the research, which were presented at the fourth meeting of The Lancet Palestinian Health Alliance in March 2012, are published online in The Lancet.
› Verified 1 days ago
| Entity Name | Randee E Lipman Md Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942570742 PECOS PAC ID: 6901864669 Enrollment ID: O20120216000344 |
News Archive
A drug designed to target cancerous plasma cells appears promising in treating multiple myeloma, a type of blood cancer. A multi-center study looked at the drug elotuzumab, an antibody which is designed to target CS1, a protein on the surface of malignant plasma cells. The antibody has the potential to attach to malignant plasma cells and eliminates them by an immune mechanism.
Fluxion Biosciences announced today a product expansion for its IonFlux automated patch clamp system which includes full automation and walk-away capability.
The U.S. Food and Drug Administration today approved the first genetic test that can help some colorectal cancer (CRC) patients and their doctors determine if the drug Erbitux (cetuximab) would be an effective treatment based on the absence of a gene mutation. The therascreen KRAS RGQ PCR Kit can provide information about the KRAS gene mutation in patients whose CRC has spread to other parts of their body (metastasized).
New research draws attention to the continuing and urgent health emergency facing Palestinians living under occupation, especially the health and wellbeing issues surrounding refugees from the occupied Palestinian territories. Abstracts of the research, which were presented at the fourth meeting of The Lancet Palestinian Health Alliance in March 2012, are published online in The Lancet.
› Verified 1 days ago
| Entity Name | Vep Hutchinson Emergency Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669879110 PECOS PAC ID: 5092031054 Enrollment ID: O20150310001308 |
News Archive
A drug designed to target cancerous plasma cells appears promising in treating multiple myeloma, a type of blood cancer. A multi-center study looked at the drug elotuzumab, an antibody which is designed to target CS1, a protein on the surface of malignant plasma cells. The antibody has the potential to attach to malignant plasma cells and eliminates them by an immune mechanism.
Fluxion Biosciences announced today a product expansion for its IonFlux automated patch clamp system which includes full automation and walk-away capability.
The U.S. Food and Drug Administration today approved the first genetic test that can help some colorectal cancer (CRC) patients and their doctors determine if the drug Erbitux (cetuximab) would be an effective treatment based on the absence of a gene mutation. The therascreen KRAS RGQ PCR Kit can provide information about the KRAS gene mutation in patients whose CRC has spread to other parts of their body (metastasized).
New research draws attention to the continuing and urgent health emergency facing Palestinians living under occupation, especially the health and wellbeing issues surrounding refugees from the occupied Palestinian territories. Abstracts of the research, which were presented at the fourth meeting of The Lancet Palestinian Health Alliance in March 2012, are published online in The Lancet.
› Verified 1 days ago
| Entity Name | Hutchinson Physicians Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427459684 PECOS PAC ID: 4183941818 Enrollment ID: O20150318000228 |
News Archive
A drug designed to target cancerous plasma cells appears promising in treating multiple myeloma, a type of blood cancer. A multi-center study looked at the drug elotuzumab, an antibody which is designed to target CS1, a protein on the surface of malignant plasma cells. The antibody has the potential to attach to malignant plasma cells and eliminates them by an immune mechanism.
Fluxion Biosciences announced today a product expansion for its IonFlux automated patch clamp system which includes full automation and walk-away capability.
The U.S. Food and Drug Administration today approved the first genetic test that can help some colorectal cancer (CRC) patients and their doctors determine if the drug Erbitux (cetuximab) would be an effective treatment based on the absence of a gene mutation. The therascreen KRAS RGQ PCR Kit can provide information about the KRAS gene mutation in patients whose CRC has spread to other parts of their body (metastasized).
New research draws attention to the continuing and urgent health emergency facing Palestinians living under occupation, especially the health and wellbeing issues surrounding refugees from the occupied Palestinian territories. Abstracts of the research, which were presented at the fourth meeting of The Lancet Palestinian Health Alliance in March 2012, are published online in The Lancet.
› Verified 1 days ago
| Entity Name | Cardio-kidney Vascular Obl Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013686781 PECOS PAC ID: 0941692933 Enrollment ID: O20220125002067 |
News Archive
A drug designed to target cancerous plasma cells appears promising in treating multiple myeloma, a type of blood cancer. A multi-center study looked at the drug elotuzumab, an antibody which is designed to target CS1, a protein on the surface of malignant plasma cells. The antibody has the potential to attach to malignant plasma cells and eliminates them by an immune mechanism.
Fluxion Biosciences announced today a product expansion for its IonFlux automated patch clamp system which includes full automation and walk-away capability.
The U.S. Food and Drug Administration today approved the first genetic test that can help some colorectal cancer (CRC) patients and their doctors determine if the drug Erbitux (cetuximab) would be an effective treatment based on the absence of a gene mutation. The therascreen KRAS RGQ PCR Kit can provide information about the KRAS gene mutation in patients whose CRC has spread to other parts of their body (metastasized).
New research draws attention to the continuing and urgent health emergency facing Palestinians living under occupation, especially the health and wellbeing issues surrounding refugees from the occupied Palestinian territories. Abstracts of the research, which were presented at the fourth meeting of The Lancet Palestinian Health Alliance in March 2012, are published online in The Lancet.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Randee E Lipman, MD 925 N Hillside St, Wichita, KS 67214-3219 Ph: (316) 616-3333 | Dr Randee E Lipman, MD 2101 N Waldron St, Hutchinson, KS 67502-1197 Ph: (620) 669-2500 |
News Archive
A drug designed to target cancerous plasma cells appears promising in treating multiple myeloma, a type of blood cancer. A multi-center study looked at the drug elotuzumab, an antibody which is designed to target CS1, a protein on the surface of malignant plasma cells. The antibody has the potential to attach to malignant plasma cells and eliminates them by an immune mechanism.
Fluxion Biosciences announced today a product expansion for its IonFlux automated patch clamp system which includes full automation and walk-away capability.
The U.S. Food and Drug Administration today approved the first genetic test that can help some colorectal cancer (CRC) patients and their doctors determine if the drug Erbitux (cetuximab) would be an effective treatment based on the absence of a gene mutation. The therascreen KRAS RGQ PCR Kit can provide information about the KRAS gene mutation in patients whose CRC has spread to other parts of their body (metastasized).
New research draws attention to the continuing and urgent health emergency facing Palestinians living under occupation, especially the health and wellbeing issues surrounding refugees from the occupied Palestinian territories. Abstracts of the research, which were presented at the fourth meeting of The Lancet Palestinian Health Alliance in March 2012, are published online in The Lancet.
› Verified 1 days ago
Moh'd Al-halawani, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1701 E 23rd Ave, Hutchinson, KS 67502 Phone: 620-513-4800 | |
Naveed Salahuddin, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2101 N Waldron St, Hutchinson, KS 67502 Phone: 620-669-2500 | |
Fadi Estephan, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2101 N Waldron St, Hutchinson, KS 67502 Phone: 620-669-2500 Fax: 620-694-2037 | |
Kristin Constance, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2100 N Waldron St Ste 5, Hutchinson, KS 67502 Phone: 620-728-1498 Fax: 620-728-1838 | |
Michael Scott Green, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2101 N Waldron St, Hutchinson, KS 67502 Phone: 620-694-4194 Fax: 620-694-2128 | |
Thoutireddy Krishna Reddy, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 2101 N Waldron St, Hutchinson, KS 67502 Phone: 620-669-2500 Fax: 620-669-2501 | |
Humayun Ashraf, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2101 N Waldron St, Hutchinson, KS 67502 Phone: 620-669-2500 Fax: 620-694-2076 |